Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.88 -2.5%	$5.34	$3.96 ▼ $9.85	$2.61B	0.41	2.62 million shs	1.54 million shs
IRON Disc Medicine	$53.38 -2.5%	$49.49	$30.82 ▼ $68.73	$1.90B	0.76	339,104 shs	195,341 shs
TARS Tarsus Pharmaceuticals	$39.93 -3.0%	$43.15	$20.08 ▼ $57.28	$1.73B	0.8	685,766 shs	486,432 shs
TECX Tectonic Therapeutic	$20.78 -2.6%	$21.32	$13.70 ▼ $61.07	$398.47M	3.17	184,185 shs	118,644 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	0.00%	+7.99%	+46.29%	+32.24%	-3.89%
IRON Disc Medicine	0.00%	+0.45%	+9.45%	+39.66%	+17.43%
TARS Tarsus Pharmaceuticals	0.00%	+1.81%	-6.47%	-13.50%	+47.35%
TECX Tectonic Therapeutic	0.00%	+9.82%	-5.70%	+40.02%	+38.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Cos	3.0314 of 5 stars	0.9	3.0	4.0	2.3	3.3	0.6
IRON Disc Medicine	2.9856 of 5 stars	4.5	1.0	0.0	2.4	2.5	0.0
TARS Tarsus Pharmaceuticals	1.9912 of 5 stars	3.5	0.0	0.0	2.9	1.7	0.6
TECX Tectonic Therapeutic	3.007 of 5 stars	3.7	1.0	0.0	3.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	1.86	Reduce	$7.42	7.80% Upside
IRON Disc Medicine	3.09	Buy	$96.70	81.15% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	66.96% Upside
TECX Tectonic Therapeutic	3.33	Buy	$83.60	302.31% Upside

Current Analyst Ratings Breakdown

Latest TECX, BHC, IRON, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
6/11/2025	TECX Tectonic Therapeutic	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00
5/15/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$51.00 ➝ $85.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$9.63B	0.26	$7.56 per share	0.91	($0.89) per share	-7.73
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
TARS Tarsus Pharmaceuticals	$182.95M	9.17	N/A	N/A	$5.87 per share	6.80
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$9.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.48	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.73	N/A	N/A	N/A	-44.91%	-39.72%	-25.74%	8/6/2025 (Estimated)
TECX Tectonic Therapeutic	-$57.98M	-$7.31	N/A	N/A	N/A	N/A	-30.13%	-27.52%	8/13/2025 (Estimated)

Latest TECX, BHC, IRON, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.9320	N/A	N/A	N/A	$2.47 billion	N/A
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	N/A	1.35	0.97
IRON Disc Medicine	0.04	37.65	37.65
TARS Tarsus Pharmaceuticals	0.21	5.57	5.54
TECX Tectonic Therapeutic	N/A	22.92	22.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
IRON Disc Medicine	83.70%
TARS Tarsus Pharmaceuticals	90.01%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	8.12%
IRON Disc Medicine	4.24%
TARS Tarsus Pharmaceuticals	8.97%
TECX Tectonic Therapeutic	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.03 million	Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	38.25 million	Optionable
TECX Tectonic Therapeutic	120	18.67 million	16.96 million	N/A

TECX, BHC, IRON, and TARS Headlines

Recent News About These Companies

Tectonic Therapeutic (NASDAQ:TECX) Rating Increased to Hold at Wall Street Zen

July 6 at 2:37 AM | americanbankingnews.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $83.60 Average PT from Analysts

July 6 at 2:40 AM | americanbankingnews.com

Tectonic Therapeutic (NASDAQ:TECX) Upgraded to "Hold" at Wall Street Zen

July 5 at 2:18 AM | marketbeat.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from Brokerages

July 3, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - Nasdaq

July 1, 2025 | nasdaq.com

Tectonic Therapeutic joins Russell 3000 index

June 30, 2025 | msn.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution

June 30, 2025 | quiverquant.comQ

Tectonic Therapeutic Joins Russell 3000® Index

June 30, 2025 | globenewswire.com

Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating

June 25, 2025 | msn.com

Tectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Wall Street Zen

June 21, 2025 | marketbeat.com

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

June 15, 2025 | finance.yahoo.com

Tectonic Therapeutic (NASDAQ:TECX) Coverage Initiated by Analysts at Raymond James

June 11, 2025 | marketbeat.com

Tectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock News

June 10, 2025 | gurufocus.com

Tectonic Therapeutic (NASDAQ:TECX) Given Average Recommendation of "Buy" by Analysts

June 8, 2025 | marketbeat.com

LifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform Recommendation

June 7, 2025 | msn.com

Tectonic Therapeutic (NASDAQ:TECX) Upgraded at Lifesci Capital

June 7, 2025 | marketbeat.com

Tectonic Therapeutic Holds 2025 Annual Stockholders Meeting

June 6, 2025 | tipranks.com

Tectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock News

June 5, 2025 | gurufocus.com

Tectonic Therapeutic Reports Q1 2025 Financial Results

May 30, 2025 | tipranks.com

Promising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45

May 22, 2025 | tipranks.com

Tectonic Therapeutic Announces Phase 1b Trial Results

May 19, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Tech Stocks You Can't Miss in This Market Cycle
By Gabriel Osorio-Mazilli | June 17, 2025
View 3 Tech Stocks You Can't Miss in This Market Cycle
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

TECX, BHC, IRON, and TARS Company Descriptions

Bausch Health Cos NYSE:BHC

$6.88 -0.18 (-2.55%)

Closing price 03:59 PM Eastern

Extended Trading

$6.89 +0.01 (+0.15%)

As of 07:06 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Disc Medicine NASDAQ:IRON

$53.38 -1.37 (-2.50%)

As of 04:00 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Tarsus Pharmaceuticals NASDAQ:TARS

$39.93 -1.22 (-2.96%)

As of 04:00 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tectonic Therapeutic NASDAQ:TECX

$20.78 -0.56 (-2.62%)

As of 04:00 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time